Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Active, not recruiting · NCT04801797 · Registry updated 2026-05-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-05-12 | NCT04801797 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Massachusetts General Hospital | 758 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atrium Health Levine Cancer Institute | Charlotte | United States | 14 |
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| City of Hope | Duarte | United States | 238 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |
| Ohio State University Medical Center | Columbus | United States | 33 |
| Stanford Cancer Center | Palo Alto | United States | 18 |
| University of California - Davis | Sacramento | United States | 9 |
| University of Pennsylvania | Philadelphia | United States | 507 |